Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?

Hematol Oncol. 2024 Mar;42(2):e3259. doi: 10.1002/hon.3259.

Authors

Andrea Duminuco^{1

2}, Antonella Nardo², Giuseppe A Palumbo^{2

3}

Affiliations

¹ Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
² Division of Hematology and BMT Unit, A.O.U. Policlinico "G.Rodolico-San Marco", Catania, Italy.
³ Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.

PMID: 38402568
DOI: 10.1002/hon.3259

No abstract available

Publication types

Letter

MeSH terms

Humans
Lymphoproliferative Disorders* / drug therapy
Nitriles*
Pyrazoles*
Pyrimidines*

Substances

ruxolitinib
Nitriles
Pyrazoles
Pyrimidines